Bibliography
- Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
- Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993;11:1936-42
- Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48
- Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26
- Baselga J, Carbonell X, Castañeda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162-71
- Slamon DL, Lejland-Jones B, Shak S, et al. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
- Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74
- Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-30
- Jahanzeb M, Mortimer JE, Yunus F, et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer. Oncologist 2002;7:410-7
- Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889-95
- Glogowska I, Sienkiewicz-Kozlowska R, Bauer-Kosinska B, et al. Trastuzumab (T) plus vinorelbine (VNR) as first-line combination in HER-2 overexpressing patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2004;23:235
- Bayo J, Mayordomo JL, Sanchez-Rovira P, et al. Trastuzumab and vinorelbine combination in the treatment of HER2 positive metastatic breast cancer. Proc Am Soc Clin Oncol 2004;23:67
- Papaldo P, Fabi A, Ferretti G, et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol 2006;17:630-6
- Chan A, Martin M, Untch M, et al. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer 2006;95:788-93
- Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007;110:965-72
- Pegram MD, Konecny GE, O'callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-49
- Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y. Antitumor activity of combination of anti-HER2-antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast ancer models. Cancer Chemother Pharmacol 2002;49:211-6
- Xu L, Song S, Zhu J, et al. Results of a phase II trial of Herceptin plus Xeloda in patients with previously untreated HER2-positive metastatic breast cancer. 27th San Antonio Breast Cancer Symposium 2004;88:Abstr.128
- Schaller G, Fuchs I, Gonsch T, et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 2007;25:3246-50
- Ishida T, Kiba T, Takeda M, et al. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2-overexpressing metastatic breast cancer after failure of both anthracyclines and taxanes. Proc Am Soc Clin Oncol 2008;26:1117
- Yamamoto D, Iwase S, Kitamura K, et al. Phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. Cancer Chemother Pharmacol 2008;61:509-14
- Christodoulou C, Fountzilas G, Razi E, et al. Gemcitabine and trastuzumab combination as salvage treatment in patients with HER2-positive metastatic breast cancer. Proc Am Soc Clin Oncol 2003;22:42
- O'shaughnessy JA, Vukelja S, Marsland T, et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 2004;5:142-7
- Brufsky A, Orlando M, Fox K, et al. Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC). First stage results. 27th San Antonio Breast Cancer Symposium 2004;88:Abstr. 3047
- O'brien Mer, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-9
- Chia S, Clemons M, Martin L, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006;24: 2773-8
- Theodoulou M, Campos S, Batist G, et al. TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol 2002;21:55
- Hancock MC, langton BC, Chan T, et al. A monoclonal antibody against c-erbB-2 proteins enhance the cytotoxicity of cisdiamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991;51:4575-80
- Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-51
- Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71
- Venturini M, Bighin C, Monfardini S, et al. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2006;95:45-53
- Yardley DA, Greco FA, Porter LL, et al. First-line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overxpressing metastatic breast cancer (HER2+ MBC): a Minnie Pearl Cancer Research Network Phase II trial. Proc Am Soc Clin Oncol 2004;22:34
- Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004;96:759-69
- Nabholtz JM, Crown J, Yonemoto L, et al. Results of two open-label multicenter pilot phase II trials of Herceptin in combination with docetaxel and platinum salts (cis- or carboplatin) as therapy for advanced breast cancer in women overexpressing HER-2. 23rd San Antonio Breast Cancer Symposium 2000;64:Abstr.83
- Fountzilas G, Christodoulou C, Tsavaridis D, et al. Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer Invest 2004;22:655-62
- Perez EA, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of paclitaxel/carboplatin/trasuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG Study 983252. Clin Breast Cancer 2005;5:425-32
- Burris III H, Yardley D, Jones S, et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004;22:1621-9
- Cortes J, Climent M, Lluch A, et al. Updated results of a phase II study (M77035) of Myocet (R) combined with weekly Herceptin (R) and paclitaxel in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (LABC/MBC). 27th San Antonio Breast Cancer Symposium 2004;88:Abstr. 3041
- Wolff AC, Bonetti M, Sparano JA, et al. Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2-positive metastatic breast cancer: preliminary results of ECOG 3198. Proc Am Soc Clin Oncol 2003;22:18
- Untch M, Eidtmann H, Du Bois A, et al. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur J Cancer 2004;40:988-97
- Wardley A, Anton-Torres A, Pivot X, et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. 30th San Antonio Breast Cancer Symposium. 2007;106: Abstr. 309
- Forbes JF, Pienkowski T, Valero V, et al. BCIRG007: randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2006;24:516
- Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer. J Clin Oncol 2006;24:2786-92
- Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocrinol Rev 2008;29:217-33
- De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11:4741-8
- Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102:43-9
- Mackey JR, Kaufman B, Clemens M, et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. 29th San Antonio Breast Cancer Symposium 2006;100:Abstr. 3
- Clemens M, Kaufman B, Mackey JR, et al. Trastuzumab plus anastrozole may prolong overall survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer: Results of a post-hoc analysis from the tandem study. 30th San Antonio Breast Cancer Symposium 2007; Abstr. 231
- Leyland-Jones B, Gelmon K, Ayoub JP, et al. Pharmacokinetics, safety and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003;21:3965-71
- Felici A, Di Segni S, Contestabile M, et al. Dose scheduling and pharmacokinetic (PK) study of trastuzumab in patients (pts) with HER2/neu overexpressing breast cancer. Proc Am Soc Clin Oncol 2007;20:1109
- Muss HB, Case LD, Richards F II, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 1991;325:1342-8
- Gregory RK, Powles TJ, Chang JC, Ashley S. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 1997;33:2194-7
- Falkson G, Gelman RS, Pandya KJ, et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998;16:1669-76
- Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22:1063-70
- Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson Cancer Center experience. J Clin Oncol 2006;24:4107-15
- Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;17:2235-49
- Yeon CH, Slamon D, Patel R, et al. Clinical benefit of trastuzumab (H) among patients with HER2-positive metastatic breast cancer (MBC) not achieving objective responses when treated with H plus chemotherapy (CT). Proc Am Soc Clin Oncol 2004;22:680
- Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-31
- Tripathy D, Hassan S, Verma U, et al. Phenotypic and proteomic alterations of acquired trastuzumab resistance. Proc Am Soc Clin Oncol 2005;23:3121
- Fujimoto-Ouchi K, Sekiguchi F, Mori K. Preclinical study of continuous administration of trastuzumab as combination therapy after disease progression with trastuzumab monotherapy. Proc Am Assoc Cancer Res 2005;46:5062
- Christodoulou C, Klouvas G, Pateli A, et al. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer. Anticancer Res 2003;23:737-44
- Fountzilas G, Razis E, Tsavdaridis D, et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer 2003;4:120-5
- Gelmon KA, Mackey J, Verma S, et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 2004;5:52-8
- Stemmler HJ, Kahlert S, Siekiera W, et al. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie 2005;28:582-6
- Garcia-Saenz JA, Martin M, Puente J, et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 2005;6:325-9
- Montemurro F, Viale G, Donadio M, et al. Retrospective evaluation of clinical outcomes in HER2-positive advanced breast cancer patients progressing on trastuzumab-based therapy in the pre-lapatinib era. 30th San Antonio Breast Cancer Symposium 2007;Abstr. 4057
- Extra JM, Antoine EC, Vincent-Salomon A, et al. Favourable effect of continued trastuzumab treatment in metastastic breast cancer patients: results from the French Hermine Cohort Study. 29th San Antonio Breast Cancer Symposium 2006;2064
- Fabi A, Metro G, Ferretti G, et al. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast 2008. In press. doi: 10.1016/j.breast.2008.03.006
- Von Minckwitz G, Zielinski C, Maartense E, et al. Capecitabine vs. capecitabine + trastuzumab in patients with HER-2 positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3-05). Proc Am Soc Clin Oncol 2008;26:1025
- Clinicaltrials.Gov: A study of Herceptin (trastuzumab) in combination with 2nd-line chemotherapy in patients with HER2 positive metastatic breast cancer. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00444587 [Last accessed 1 July 2008]
- Clinicaltrials.Gov: THOR Study: a study of continued Herceptin (trastuzumab) in combination with second line chemotherapy in patients with HER2 positive metastatic breast cancer. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00448279 [Last accessed 1 July 2008]
- Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972-7
- Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004;91:639-43
- Gori S, Rimondini S, De Angelis V, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 2007;12:766-73
- Metro G, Sperduti I, Russillo M, et al. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. Oncologist 2007;12:1467-9
- Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006;17:935-44
- Stemmler HJ, Schmitt M, Willems A, et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier. Anticancer Drugs 2007;18:23-8
- Kirsch DG, Ledezma CJ, Mathews CS, et al. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol 2005;23:2114-6
- Dawood S, Broglio K, Esteva FJ, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008;19:1242-8
- Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008. In press. doi:10.1007/s10549-007-9885-0
- Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26:1993-9
- Lin NU, Dieras V, Paul D, et al. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). Proc Am Soc Clin Oncol 2007;25:1012
- Clynes RA, Towers TL, Presta LG, Ravetch JM. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:373-4
- Molina MA, Codony-Servat J, Albanell J, et al. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61:4744-9
- Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-41
- Izumi Y, Xu L, Di Tomaso E, et al. Tumor biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002;416:279-80
- Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27
- Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402
- Mottolese M, Fabi A, Nisticò C, et al. PTEN and phospho-MAP kinase are independent predictors of response only in metastatic breast cancer patients treated with trastuzumab plus chemotherapy as first-line option. 29th San Antonio Breast Cancer Symposium 2006;Abstr. 3046
- Nahta R, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65:1118-28
- Valabrega G, Montemurro F, Sarotto I, et al. TGFalpha expression impairs trastuzumab-induced HER2 downregulation. Oncogene 2005;24:3002-10
- Nagy P, Friedländer E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005;65:473-82
- Bussolati G, Montemurro F, Righi L, et al. Modified trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. Br J Cancer 2005;92:1261-7
- Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37
- Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-9
- Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004;23:646-53
- Scaltriti M, Rojo F, Ocaña A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99:628-38
- Burris HA III, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-13
- Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008;19:1068-74
- Schwartz G, Chu Qs-C, Hammond LA, et al. Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2004;22:3070
- Jones S, Burris III HA, Yardley D, et al. Lapatinib (an oral dual kinase inhibitor) plus weekly or every 3 week paclitaxel. 27th San Antonio Breast Cancer Symposium 2004;Abstr. 1069
- Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43
- Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for erbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26:2999-3005
- O'shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Proc Am Soc Clin Oncol 2008;26:1015
- Clinicaltrials.Gov: ALTTO (adjuvant lapatinib and/or trastuzumab treatment optimisation) Study; BIG 2-06/N063D Available from: http://clinicaltrials.gov/ct2/results?term=NCT00490139 [Last accessed 1 July 2008]
- Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343-6
- Gelmon KA, Fumoleau P, Verma S, et al. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients who had progressed during trastuzumab therapy. Proc Am Soc Clin Oncol 2008;26:1026
- Portera CC, Walshe JM, Rosing DR, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008;14:2710-6
- Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005;23:4553-60
- Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;27(57):2666-76
- Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Proc Am Soc Clin Oncol 2008;26:1011
- Yen L, You XL, Al Moustafa AE, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000;19:3460-9
- Konecny GE, Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10:1706-16
- Pegram MD, yeon C, Ku NC, et al. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). 27th San Antonio Breast Cancer Symposium 2004;Abstr. 3039
- Pegram M, Chan D, Dichmann RA, et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vacular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first-line treatment of HER2-amplified breast cancer. 29th San Antonio Breast Cancer Symposium 2006; Abstr.301
- Clinicaltrials.Gov: a study of avastin (bevacizumab) in combination with Herceptin (trastuzumab)/docetaxel in patients with HER2 positive metastatic breast cancer. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00391092 [Last accessed 1 July 2008]
- Rugo H, Franco S, Stopeck A, et al. Phase II evaluation of lapatinib and bevacizumab in HER2+ metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2008;26:1042
- Slamon D, Gomez H, Kabbinawar F, et al. Randomized phase II study of pazopanib + lapatinib vs lapatinib alone in patients with HER2+ advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 2008;26:1016
- Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 2004;82(8):488-9
- Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007;25:5410-7
- Modi S, Sugarman A, Stopeck A, et al. Phase II trial of the inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2 positive metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2008;26:1027
- Beeram M, Burris III HA, MODI S, et al. A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer. Proc Am Soc Clin Oncol 2008;26:1028
- clinicaltrials.Gov: A study of trastuzumab-MCC-DM1 administered intravenously to patients with her2-positive metastatic breast cancer. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00509769 [Last accessed 1 July 2008]
- Clinicaltrials.Gov: Phase II study with the trifunctional antibody ertumaxomab to treat metastatic breast cancer after progression on trastuzumab therapy. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00522457 [Last accessed 1 Jul 2008]
- Andre F, Campone M, Hurvitz S, et al. Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. Proc Am Soc Clin Oncol 2008;26:1003
- Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13:3109-14
- Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004;164:769-79
- Liu PC, Liu X, Li Y, et al. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther 2006;5:657-64
- Pestalozzi B, Castiglione M. SMO GUIDELINES WORKING GROUP: primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl l2):7-10
- Metro G, Fabi A, Giannarelli D, et al. Time to first tumor progression as outcome predictor of a second trastuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer. Proc Am Soc Clin Oncol 2008;26:1071